# Supplementary Material

Supplementary Table. HIV Antiretroviral Therapies

| **Class** | **Drug name(s)** |
| --- | --- |
| CYP3A inhibitors | cobicistat |
| Entry inhibitors | maraviroc |
| Fusion inhibitors | enfuvirtide |
| Integrase inhibitors | dolutegravir  raltegravir  elvitegravir |
| Multi-class combinations | efavirenz / emtricitabine / tenofovir DF  emtricitabine / rilpivirine / tenofovir DF  elvitegravir / cobicistat / emtracitabine / tenofovir DF  abacavir / dolutegravir / lamivudine |
| NNRTIs | delavirdine  efavirenz  nevirapine  rilpivirine  etravirine |
| NRTIs | emtricitabine  lamivudine  zidovudine, azidothymidine  didanosine  tenofovir DF  stavudine  abacavir  zalcitabine, dideoxycytidine |
| NRTI combinations | lamivudine / zidovudine  abacavir / lamivudine  abacavir / lamivudine / zidovudine  emtricitabine / tenofovir DF |
| Protease inhibitors | amprenavir  fosamprenavir  tipranavir  indinavir  darunavir  saquinavir  saquinavir mesylate  ritonavir  atazanavir  nelfinavir mesylate |
| Protease inhibitor combinations | lopinavir / ritonavir  atazanavir / cobicistat  darunavir / cobicistat |

CYP3A, cytochrome P4503A; DF, disoproxil fumarate; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside/ nucleotide reverse transcriptase inhibitor.